Advertisement

Conformation-activity relationships of cyclo-constrained μ/5 opioid agonists derived from the N-terminal tetrapeptide segment of dermorphin/deltorphin

  • Jerzy Ciarkowski
  • Cezary Czaplewski
  • Sylwia Luczak
  • Sylwia Rodziewicz-Motowidlo
  • Irena Berezowska
  • Peter W. Schiller
Part of the Advances in Experimental Medicine and Biology book series (volume 611)

Introduction

The N-terminal tetrapeptide segments of dermorphin (Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH 2) and deltorphin (Tyr-D-Ala-Phe-Asp/Glu-Val-Val-Gly-NH 2) are agonists at the opioid receptors μ and δ, respectively. (D-Arg 2,Lys 4)-dermorphin(1–4) amide (Tyr-D-Arg-Phe-Lys-NH 2, DALDA) and [Dmt 1]DALDA (Dmt is 2′,6′-dimethyl-tyrosine) are among the most potent and selective μ-agonists reported to date, both in vitro (the latter one having picomolar μ receptor affinity) and in vivo. In this communication, conformation-activity studies of cyclic tetrapeptide analogs of dermorphin/deltorphin are presented and discussed. They include the peptide Tyr-c[D-Cys-Phe-Cys]NH 2, constrained via an S yS ′y disulfide between Cys 2 and Cys 4, and its dicarba analogs, the C yC ′y-saturated and -olefinic ones. They are potent nonselective or moderately μ-selective opioid agonists in vitro [ 1] (Table 1). With a major structural constraint imposed by the 11-membered ring spanning residues 2–4, they are expected to...

Keywords

Opioid Agonist Proton Chemical Shift Agonist Potency Spectrum TOCSY Flexible Peptide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

This work was funded by Polish Ministry of Science and Higher Education (grants BW/8000-5-0376-7, BW/8000-5-0058-7) and by grants from the CIHR and NIH.

References

  1. 1.
    Berezowska, I., Chung, N.N., Lemieux, C., Wilkes, B.C. and Schiller, P.W. Acta Biochim. Polon. 53, 73–76 (2006).Google Scholar
  2. 2.
    ACD/Labs, Toronto, Ontario, Canada M5C 1T4, Copyright © 1994–2004.Google Scholar
  3. 3.
    Bartles, C., Xia, T., Billeter, M., Günter, P. and Wütrich, K. J. Biomol NMR 6, 1–10 (1995).CrossRefGoogle Scholar
  4. 4.
    Pearlman, D.A. J. Biomol. NMR 4, 1–16 (1994).Google Scholar
  5. 5.
    Case, D.A., Darden, T.A., Cheatham, III, T.E., Simmerling, J.C.L., et al and Kollman, P.A., AMBER 8, University of California, San Francisco (2004).Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Jerzy Ciarkowski
    • 1
  • Cezary Czaplewski
    • 1
  • Sylwia Luczak
    • 1
  • Sylwia Rodziewicz-Motowidlo
    • 1
  • Irena Berezowska
    • 2
  • Peter W. Schiller
    • 2
  1. 1.Faculty of ChemistryUniversity of GdanskGdanskPoland
  2. 2.Clinical Research Institute of MontrealMontrealCanada

Personalised recommendations